INTERCEPT-AD Biomarker Results: Early Effect of Sabirnetug Treatment on Synaptic Biomarkers in Alzheimer’s Disease (P12-3.003)
To examine early effects of sabirnetug (ACU193) on cerebrospinal fluid (CSF) levels of synaptic biomarkers in study participants with early symptomatic Alzheimer’s disease (AD).
Authors
- Michael E. Hyland (ORCID: https://orcid.org/0000-0003-3879-0469)
- Hugo Vanderstichele
- Daniel Antwi‐Berko (ORCID: https://orcid.org/0000-0001-8994-1349)
- Hao Zhang (ORCID: https://orcid.org/0000-0002-7377-0589)
- Erika N. Cline (ORCID: https://orcid.org/0000-0001-8062-4312)
- Charlotte Elisabeth Teunissen (ORCID: https://orcid.org/0000-0002-4061-0837)
- Jasna Jerecı̀ć
- Eric Siemers
- June Kaplow
- Elizabeth A. Johnson (ORCID: https://orcid.org/0000-0002-3914-6600)
- Robert A. Dean
- Karen Sundell
- Gopalan Sethuraman
- Marleen J.A. Koel‐Simmelink (ORCID: https://orcid.org/0000-0003-3939-7394)
Institutions
- Amsterdam University Medical Centers (NL)
- Acumen Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211373
- Primary Topic
- Biological and pharmacological studies of plants
- Type
- article
- Field-Weighted Citation Impact
- 0.00